Clinical trial
Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With…
NCT00064610 · Millennium Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00064610 |
|---|---|
| Title | Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer |
| Official title | A Phase I/II, Open Label, Dose Escalation Study to Determine the Tolerance and Preliminary Activity of PS-341 Plus Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer Requiring Chemotherapy |
| Lead sponsor | Millennium Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Drug |
| Interventions | VELCADE TM (bortezomib) for Injection |
| Enrollment | 102 |
| Start date | Dec 1, 2002 |
| Primary completion | Dec 1, 2004 |
| First posted | Jul 11, 2003 |
| Last update posted | Feb 11, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: